Please login to the form below

Not currently logged in


This page shows the latest Epidiolex news and features for those working in and with pharma, biotech and healthcare.

Medical cannabis now available on prescription, for some

Medical cannabis now available on prescription, for some

Meanwhile, GW Pharma – which has been cultivating medicinal cannabis in the UK for more than 20 years – just recently got approval and favourable scheduling for its cannabis-based epilepsy therapy Epidiolex

Latest news

  • US approval for first ever cannabis-based medicine US approval for first ever cannabis-based medicine

    Once this recategorisation is completed within the next 90 days, GW Pharma will launch Epidiolex in the US. ... Phase 3 studies showed Epidiolex added to other epilepsy therapies significantly reduced the frequency of seizures in patients with LGS and

  • The year of the blockbuster The year of the blockbuster

    Epidiolex from GW Pharmaceuticals:With a PDUFA date in June, GW Pharmaceuticals’ Epidiolex (plant-derived cannabidiol) has the potential to become the first cannabinoid-based anti-epileptic medication. ... The industry will watch carefully whether

  • GW ascendant as epilepsy drug clears phase III trial GW ascendant as epilepsy drug clears phase III trial

    The 120-patient study revealed that patients given Epidiolex saw a 39% median reduction in monthly seizures after 14 weeks' treatment, compared to a 13% cut in the placebo group. ... GW has been scaling up its commercial organisation and production

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Jet Off with Maloff Protect

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...